Allergic reaction triggers FDA hold on Pluristem trial; shares plunge
This article was originally published in Scrip
Panicked investors drove shares of Pluristem Therapeutics down as low as 26% on 4 June after the company revealed the US FDA had slapped a clinical hold on the Israeli firm's Phase II trial of its experimental placenta-based cell therapy, PLX-PAD, under investigation for intermittent claudication (IC) after one of the 74 enrolled patients was hospitalized after experiencing a serious allergic reaction.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.